Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Trends in Anaesthesia and Critical Care ; 42:43-48, 2022.
Artigo em Inglês | EMBASE | ID: covidwho-2084475

RESUMO

Airway management, including tracheal intubation and tracheostomy, is the most commonly performed procedure in critically ill patients. The EAMS held a webinar in June 2021 focused on this subject. Vincenzo Russotto from Monza, Italy and Sheila Myatra from Mumbai, India presented the results of the "INternational observational study To Understand the impact and BEst practices of airway management in critically ill patients", the INTUBE study. The attendees of the EAMS webinar asked questions related to the study and the complications in critically ill patients. The present article summarises the discussion together with strategies to help clinicians prevent and treat these complications. Copyright © 2021 Elsevier Ltd

2.
Jama-Journal of the American Medical Association ; 327(3):286-286, 2022.
Artigo em Inglês | Web of Science | ID: covidwho-1695638
3.
Acta Anaesthesiol Scand ; 65(6): 834-845, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: covidwho-1083073

RESUMO

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in millions of deaths and overburdened healthcare systems worldwide. Systemic low-dose corticosteroids have proven clinical benefit in patients with severe COVID-19. Higher doses of corticosteroids are used in other inflammatory lung diseases and may offer additional clinical benefits in COVID-19. At present, the balance between benefits and harms of higher vs. lower doses of corticosteroids for patients with COVID-19 is unclear. METHODS: The COVID STEROID 2 trial is an investigator-initiated, international, parallel-grouped, blinded, centrally randomised and stratified clinical trial assessing higher (12 mg) vs. lower (6 mg) doses of dexamethasone for adults with COVID-19 and severe hypoxia. We plan to enrol 1,000 patients in Denmark, Sweden, Switzerland and India. The primary outcome is days alive without life support (invasive mechanical ventilation, circulatory support or renal replacement therapy) at day 28. Secondary outcomes include serious adverse reactions at day 28; all-cause mortality at day 28, 90 and 180; days alive without life support at day 90; days alive and out of hospital at day 90; and health-related quality of life at day 180. The primary outcome will be analysed using the Kryger Jensen and Lange test adjusted for stratification variables and reported as adjusted mean differences and median differences. The full statistical analysis plan is outlined in this protocol. DISCUSSION: The COVID STEROID 2 trial will provide evidence on the optimal dosing of systemic corticosteroids for COVID-19 patients with severe hypoxia with important implications for patients, their relatives and society.


Assuntos
Anti-Inflamatórios/administração & dosagem , Tratamento Farmacológico da COVID-19 , Dexametasona/administração & dosagem , Pandemias , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , SARS-CoV-2 , Anti-Inflamatórios/efeitos adversos , COVID-19/complicações , Dinamarca , Dexametasona/efeitos adversos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Mortalidade Hospitalar , Humanos , Hidrocortisona/uso terapêutico , Hipóxia/tratamento farmacológico , Hipóxia/etiologia , Índia , Cuidados para Prolongar a Vida/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Qualidade de Vida , Análise de Sobrevida , Suécia , Suíça
4.
Anaesthesia ; 75(11): 1437-1447, 2020 11.
Artigo em Inglês | MEDLINE | ID: covidwho-591680

RESUMO

Healthcare workers involved in aerosol-generating procedures, such as tracheal intubation, may be at elevated risk of acquiring COVID-19. However, the magnitude of this risk is unknown. We conducted a prospective international multicentre cohort study recruiting healthcare workers participating in tracheal intubation of patients with suspected or confirmed COVID-19. Information on tracheal intubation episodes, personal protective equipment use and subsequent provider health status was collected via self-reporting. The primary endpoint was the incidence of laboratory-confirmed COVID-19 diagnosis or new symptoms requiring self-isolation or hospitalisation after a tracheal intubation episode. Cox regression analysis examined associations between the primary endpoint and healthcare worker characteristics, procedure-related factors and personal protective equipment use. Between 23 March and 2 June 2020, 1718 healthcare workers from 503 hospitals in 17 countries reported 5148 tracheal intubation episodes. The overall incidence of the primary endpoint was 10.7% over a median (IQR [range]) follow-up of 32 (18-48 [0-116]) days. The cumulative incidence within 7, 14 and 21 days of the first tracheal intubation episode was 3.6%, 6.1% and 8.5%, respectively. The risk of the primary endpoint varied by country and was higher in women, but was not associated with other factors. Around 1 in 10 healthcare workers involved in tracheal intubation of patients with suspected or confirmed COVID-19 subsequently reported a COVID-19 outcome. This has human resource implications for institutional capacity to deliver essential healthcare services, and wider societal implications for COVID-19 transmission.


Assuntos
Betacoronavirus , Infecções por Coronavirus/transmissão , Pessoal de Saúde , Intubação Intratraqueal , Exposição Ocupacional/efeitos adversos , Pneumonia Viral/transmissão , Adulto , COVID-19 , Infecções por Coronavirus/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/epidemiologia , Modelos de Riscos Proporcionais , Estudos Prospectivos , Risco , SARS-CoV-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA